Loading clinical trials...
Loading clinical trials...
A Prospective, Multi-Center Study of the Braive™ Growth Modulation System When Used in the Treatment of Pediatric Patients Diagnosed With Juvenile or Adolescent Idiopathic Scoliosis
The purpose of this study was to establish probable benefits and evaluate the safety and preliminary effectiveness of the Braive™ GMS when used in the treatment of pediatric progressive scoliosis.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Mayo Clinic
Rochester, Minnesota, United States
IWK Health Centre
Halifax, Nova Scotia, Canada
Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada
The Newcastle upon Tyne Hospitals NHS Foundation Trust - Royal Victoria Infirmary
Newcastle upon Tyne, United Kingdom
Start Date
August 12, 2021
Primary Completion Date
April 11, 2025
Completion Date
January 14, 2026
Last Updated
March 20, 2026
10
ACTUAL participants
Braive™ Growth Modulation System (Braive™ GMS)
DEVICE
Lead Sponsor
Medtronic Spinal and Biologics
NCT06365892
NCT04761549
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06314594